Some ICIs are now approved by drug agencies, such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) (Drugs@FDA, 2021), for use in oncotherapy to reduce the suppression of effector T cells, especially CD8+, improving tumor-specific immune responses (Dyck and Mills, 2017). The gene discussed is CD8A; the disease is neoplasm.